Compounds > lasofoxifene

Page last updated: 2024-09-05

lasofoxifene and Osteoporosis

lasofoxifene has been researched along with Osteoporosis in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (9.09)	18.2507
2000's	7 (63.64)	29.6817
2010's	3 (27.27)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Pinkerton, JV; Thomas, S	1
de Villiers, TJ	1
Silverman, SL	1
Cappon, GD; Horimoto, M; Hurtt, ME	1
Cappon, GD; Gupta, U; Hurtt, ME; Tassinari, MS; Terry, KK	1
Hagler, AR; Tassinari, MS; Weisenburger, WP	1
Chaki, O	1
Chidsey-Frink, KL; Crawford, DT; Ke, HZ; Qi, H; Simmons, HA; Thompson, DD	1
Chidsey-Frink, KL; Crawford, DT; Ke, HZ; Qi, H; Thompson, DD	1

Reviews

5 review(s) available for lasofoxifene and Osteoporosis

Article	Year
Use of SERMs for treatment in postmenopausal women. The Journal of steroid biochemistry and molecular biology, 2014, Volume: 142 Topics: Breast Neoplasms; Clinical Trials as Topic; Dyspareunia; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Toremifene	2014
The quest for new drugs to prevent osteoporosis-related fractures. Climacteric : the journal of the International Menopause Society, 2017, Volume: 20, Issue:2 Topics: Benzoates; Biphenyl Compounds; Bone Density Conservation Agents; Drug Discovery; Humans; Osteoporosis; Osteoporotic Fractures; Piperidines; Propanolamines; Pyrrolidines; Tetrahydronaphthalenes; Thiophenes	2017
New selective estrogen receptor modulators (SERMs) in development. Current osteoporosis reports, 2010, Volume: 8, Issue:3 Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Indoles; Osteoporosis; Piperidines; Pyrrolidines; Risk Factors; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes	2010
Lasofoxifene: CP 336156, CP-336156. Drugs in R&D, 2005, Volume: 6, Issue:1 Topics: Adult; Aged; Animals; Atrophy; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Musculoskeletal Diseases; Osteoporosis; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Vaginal Diseases	2005
[Next generation selective estrogen receptor modulators]. Clinical calcium, 2006, Volume: 16, Issue:1 Topics: Animals; Bone Density; Bone Density Conservation Agents; Cholesterol; Female; Humans; Indoles; Osteoporosis; Pyrrolidines; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Uterus	2006

Other Studies

6 other study(ies) available for lasofoxifene and Osteoporosis

Article	Year
Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in male rats. Birth defects research. Part B, Developmental and reproductive toxicology, 2004, Volume: 71, Issue:3 Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Embryo, Mammalian; Epididymis; Estrogens; Female; Fertility; Male; Organ Size; Osteoporosis; Paternal Exposure; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reproduction; Selective Estrogen Receptor Modulators; Seminal Vesicles; Sperm Motility; Tetrahydronaphthalenes; Time Factors	2004
Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats. Birth defects research. Part B, Developmental and reproductive toxicology, 2004, Volume: 71, Issue:3 Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Embryo Implantation; Embryo, Mammalian; Estrogens; Estrous Cycle; Female; Fertility; Male; Maternal Exposure; Osteoporosis; Parturition; Pregnancy; Pregnancy, Animal; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reproduction; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Time Factors	2004
Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats. Birth defects research. Part B, Developmental and reproductive toxicology, 2004, Volume: 71, Issue:3 Topics: Animals; Behavior, Animal; Body Temperature; Body Weight; Dose-Response Relationship, Drug; Embryo, Mammalian; Embryonic Development; Estrogens; Feeding Behavior; Female; Lactation; Male; Maternal Exposure; Maze Learning; Osteoporosis; Parturition; Pregnancy; Pregnancy, Animal; Prenatal Exposure Delayed Effects; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reproduction; Risk; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Time Factors	2004
CP 336156. Drugs in R&D, 1999, Volume: 1, Issue:3 Topics: Animals; Drugs, Investigational; Estrogen Antagonists; Female; Haplorhini; Humans; Male; Osteoporosis; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes	1999
Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology, 2000, Volume: 141, Issue:4 Topics: Aging; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Cholesterol; Estrogen Antagonists; Femur; Lumbar Vertebrae; Male; Orchiectomy; Organ Size; Osteoporosis; Prostate; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tetrahydronaphthalenes	2000
Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2001, Volume: 16, Issue:4 Topics: Adipose Tissue; Aging; Animals; Body Composition; Bone and Bones; Bone Density; Bone Resorption; Cholesterol; Drug Evaluation, Preclinical; Elasticity; Femur; Hypercholesterolemia; Lumbar Vertebrae; Male; Organ Size; Osteocalcin; Osteoclasts; Osteoporosis; Prostate; Pyrrolidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Stress, Mechanical; Tetrahydronaphthalenes; Tibia; Tomography, X-Ray Computed	2001